Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: iron oxide red; maize starch; calcium hydrogen phosphate dihydrate; mannitol; magnesium stearate - hypertension: for treatment of hypertension, lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: for treatment of heart failure, it is recommended that lisinopril be administered with a diuretic. acute myocardial infarction: for treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg, lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; mannitol; iron oxide red; maize starch - hypertension: for treatment of hypertension, lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: for treatment of heart failure, it is recommended that lisinopril be administered with a diuretic. acute myocardial infarction: for treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg, lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: iron oxide red; maize starch; magnesium stearate; calcium hydrogen phosphate dihydrate; mannitol - hypertension: for treatment of hypertension, lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: for treatment of heart failure, it is recommended that lisinopril be administered with a diuretic. acute myocardial infarction: for treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg, lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; iron oxide red; calcium hydrogen phosphate dihydrate; mannitol; maize starch - hypertension: for treatment of hypertension, lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: for treatment of heart failure, it is recommended that lisinopril be administered together with a diuretic. acute myocardial infarction: for treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg, lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; iron oxide red; mannitol; maize starch - hypertension: for treatment of hypertension, lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: for treatment of heart failure, it is recommended that lisinopril be administered together with a diuretic. acute myocardial infarction: for treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg, lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: maize starch; calcium hydrogen phosphate dihydrate; iron oxide red; mannitol; magnesium stearate - hypertension: for treatment of hypertension, lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: for treatment of heart failure, it is recommended that lisinopril be administered together with a diuretic. acute myocardial infarction: for treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg, lisinopril may be initiated within 24 hours of an acute myocardial infarction.